Shire’s new drug sales offset 74% decline in Adderall

Declining sales of its now off-patent drug Adderall XR continue to weigh on Shire, the speciality pharmaceutical group, although strong growth in sales of new drugs…

source : traxfer.ft.com

Related News:

• Kidney Cancer Drug Shows Promising Results
• AM: Drug for Fibromyalgia Boosts Multiple Outcomes (CME/CE)
• Access Pharmaceuticals Initiates Program Applying Cobalamin Platform To SiRNA Drug Delivery
• Auxilium Announces U.S. Food And Drug Administration Approval For XIAFLEXTM For The Treatment Of Dupuytren’s Contracture
• Possible New Drug Target For Iron Deficiency, Overload
• Targeted Oral Drug Pazopanib Slows Progression Of Advanced Kidney Cancer
• Using Zebrafish As A Novel Platform For Drug Development
• PSivida CEO To Discuss Ocular Drug Delivery In Diabetic Retinopathy At 6th Annual Diabetes Conference January 22 In London
• Abnormal Lipid Levels Common in Teens
• FDA Adds Cardio Warnings to Weight Loss Drug

Details :
Submited at Saturday, October 31st, 2009 at 12:00 am on Pharmaceutical by admin
Comment RSS 2.0 - leave a comment - trackback